Skip to content
Screener

Nektar Therapeutics NKTR Q2 2025 earnings

Reported August 7, 2025 · After market close

Revenue$11.2MBeat by $1.8M
EPS-$2.95Beat by $0.18
Revenue estimate$9.4M
EPS estimate-$3.13

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$10.4M
EPS estimate-$2.13

Financials

Q2 2025

Income statement

See full
Revenue$11.2M-52.4%
Gross profit$11.2M-18.7%
Operating income-$36.2M+27.2%
Net income-$41.6M+20.6%
EPS (diluted)-$2.95+21.5%

Balance sheet

See full
Cash & equivalents$6.3M-38.9%
Total debt$96.2M-14.2%
Total equity-$24.2M-130%
Total assets$207.5M-39.6%

Cash flow

See full
Operating cash flow-$45.7M-21.3%
CapEx$37.0K-80.1%
Free cash flow-$45.8M-20.8%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$303.35M+25.6%
Enterprise value$393.17M+14.6%
P/S4×+1.5×

Profitability

See full
Gross margin83.4%+24.2pp
Net margin-172.9%-14.4pp
FCF margin-248.3%+116pp

Returns & leverage

See full
Current ratio2.6×-2.5×

Segments

By geography

See full
Non Us$13.8M-43.1%

By product

See full
Non Cash Royalty Revenue Related To Sale Of Future Royalties$11.2M-33.3%

FAQ

When did Nektar Therapeutics report Q2 2025 earnings?
Nektar Therapeutics (NKTR) reported Q2 2025 earnings on August 7, 2025 after market close.
What were Nektar Therapeutics's Q2 2025 revenue and EPS?
Nektar Therapeutics reported revenue of $11.2M and eps of $-2.95 for Q2 2025.
Did Nektar Therapeutics beat estimates in Q2 2025?
Revenue beat the consensus estimate of $9.4M by $1.8M. EPS beat the consensus estimate of $-3.13 by $0.18.
How did Nektar Therapeutics's Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 52.4% from $23.5M a year earlier and eps declined 1080.0% from $-0.25.
Where can I find Nektar Therapeutics's Q2 2025 SEC filings?
You can read the 8-K earnings release (0001213900-25-073100) and the 10-Q periodic report (0000950170-25-105275) directly on SEC EDGAR. The filing index links above go to sec.gov.